Neuropilin-2, The Specific Binding Partner To ATYR1923, is Expressed In Sarcoid Granulomas and Key Immune Cells Suzanne Paz, Dalena Chu, Michaela Ferrer, Kendall Walwick, Clara Polizzi, Jeanette Ampudia, Steve Crampton, Christoph Burkart, Leslie Nangle, Sanna Rosengren aTyr Pharma, San Diego, California, USA

Abstract

Neuropilin-2 (NRP2) is a pleiotropic co-receptor with an emerging role in the regulation of inflammatory responses. NRP2 was identified by aTyr as the sole binding partner for ATYR1923, a fusion protein combining a novel immunomodulatory domain from histidyl-tRNA synthetase (HARS) and a human IgG1 Fc. ATYR1923 is in early clinical testing for pulmonary sarcoidosis, an inflammatory condition that can lead to lung fibrosis. To date, little is known about the role of NRP2 in immune regulation and disease, in particular very little is known about the expression of NRP2 in sarcoidosis patients. We sought to characterize NRP2 expression patterns on immune cells implicated in the pathology of sarcoidosis.

Using RNAscope® technology, we demonstrate that NRP2 mRNA is present in both skin and lung samples obtained from sarcoidosis patients. NRP2 expression was readily detectable in granulomas with positive signals predominantly localized within the inner structure of the granuloma where Langham's giant cells (myeloid origin) reside. This finding was confirmed in both lung and skin samples from sarcoidosis patients. We thus sought to investigate which immune cells express NRP2.

In vitro, we show that NRP2 is highly inducible in key immune cells following immunomodulatory insults such as lipopolysaccharide (LPS) or other toll-like-receptor ligands (TLR). Interestingly, NRP2 expression on macrophages was only induced following activation of toll-like receptors found on the cell surface (TLR1, TLR2, TLR4, TLR5, TLR6), but not by endosomal TLR ligands (TLR3, TLR7/8, TLR9). In addition to detecting NRP2 on the cell surface of macrophages, we also confirm its presence on dendritic cells, T cells and T regulatory cells using either cell lines or primary cells.

In vivo, multi-color flow cytometry was used to immunophenotype either lungs or spleens isolated from LPS challenged animals. We confirmed our in vitro findings demonstrating that expression of NRP2 is present and inducible on the cell surface of various immune cells (macrophages, dendritic cells, neutrophils, and T cells).

We report for the first time that NRP2 is expressed in samples obtained from lung and skin of sarcoidosis patients. We clearly show that NRP2 expression can be detected on key immune cells known to play an important role in inflammation and granuloma formation. These findings highlight the potential of ATYR1923 to exert its effect on various immune cells directly related to the pathology of the target patient population.

Introduction

- Sarcoidosis is an inflammatory disorder of unknown etiology
- The disease involves granuloma formation (clumps of inflammatory cells) in affected organs, which can lead to fibrosis and irreversible organ damage. Lungs are the most commonly affected organ (>90% of cases) and this is referred to as pulmonary sarcoidosis
- We previously demonstrated that ATYR1923, a fusion protein combining a novel immunomodulatory domain from histidyl-tRNA synthetase (HARS) and a human IgG1 Fc binds to the NRP2 receptor in human and mouse overexpressing cells (Paz et al., Keystone 2019; Xu et al., ATS 2020)
- Little is known about NRP2's role in immune regulation and disease/granuloma progression

Figure 1. An unknown antigen activates (A) interstitial DCs, (B) alveolar macrophages (AMs), and (C) alveolar epithelial cells type II (AEC-II). This process is possibly initiated by TLR-2 ligands. (A) The interstitial DCs pick up the antigen and migrate toward the mediastinal lymph nodes (LNs), where they initiate differentiation and clonal expansion of T helper (Th)1 and 17 ligands under stimulation of both TNF-α and natural-killer (NK) cell-derived INF-γ, thereby attracting Th1/17 cells, monocytes, regulatory T cells (Tregs), and B cells. (C) The lung environment is characterized by the presence of Th1 and Th17 favoring cytokines produced by macrophages, DCs, and AEC-II. Persistent stimulation, mediated by APCs, leads to continuous cellular cells. (B) Simultaneously, AMs produce TNF-α, which initiates upregulation of activation (HLA-DR and CD80/86) and adhesion (ICAM-1 and LeuCAM) molecules. Macrophages produce chemokine recruitment to the site of inflammation, which leads to granuloma formation. Tregs infiltrating the granuloma fail to diminish the exaggerated immune response, thereby contributing to granuloma persistence and integrity.

Experimental Procedure

Figure 2. RNAscope® Methodology
$\begin{array}{ccc} \text{PERMEABILIZE} \\ \text{cells or tissue} \end{array} \rightarrow \begin{array}{c} \text{HYBRIDIZE} \\ \text{to target RNA} \end{array} \rightarrow \begin{array}{c} \text{AMPLIFY} \\ \text{signal} \end{array} \rightarrow \begin{array}{c} \text{VISUALIZE} \\ \text{with morphology} \end{array} \rightarrow \begin{array}{c} \text{QUANTIFY} \\ \text{single-cell expression} \end{array}$
Figure 2. Schematic Representation showing the experimental procedures utilized to measure NRP2 mRNA expression in skin and lung biopsy samples. Briefly, fixed tissue sections on slides were pretreated with a pretreatment kit to block endogenous peroxidase activity and optimally permeabilize samples to allow probe access to target RNA. With approximately 20 specific double Z probe pairs per target, probes hybridize to target RNA molecules. Detection reagents amplify the hybridization signals via sequential hybridization of amplifiers and labeled probes. Each punctuated dot signal represents a positive signal.
Figure 3. Generation of Human Primary Macrophages
Macrophages Macrophages Macrophages Macrophages Macrophages Macrophages Macrophages Macrophages Macrophages
Figure 4. Generation of Human Macrophages from THP-1 Cell Line



and stained for flow cytometry analysis.

Results Figure 10. NRP2 Expression on Human Primary Dendritic Cells **Figure 7. NRP2 Expression in Sarcoid Samples** Lung Sample **Skin Sample** NRP2 Expression on DCs **2 hours:** 50 ng/ml GM-CSF 120 hours: 50 ng/ml GM-CSF 120 hours: 50 ng/mllL-4 72 hours: 50 ng/mllL-4 **168 hours:** 50 ng/mlIL-4 FL1-A :: FITC-A Comp-FL1-A :: FITC-A Comp-FL1-A :: FITC-A Comp-FL1-A :: FITC-A CD14+CD16 Mature DCs mmature DC Figure 10. Histogram representation of NRP2 expression detected on the cell surface of primary human DCs at Day 0, 3, 5 and 7 generated from CD14+CD16- monocytes. Bar graph representation of NRP2 MFI mean values +/- SEM. Granuloma Granulomas **Figure 11. NRP2 Expression on Human Inducible Tregs** Figure 7. NRP2 Expression in Granuloma from Sarcoid A) Lung and B) Skin biopsies. Representative image of NRP2 ISH staining (red dots) in lung granulomas (A) and skin granulomas (B). A total of four lung samples and four skin samples were analyzed. NRP2 expression was low to moderate levels across the sample with high expression in granulomas +αCD3/CD28 tetrame +aCD3/CD28tet from either lung or skin samples. **Figure 8. NRP2 Expression on Primary Macrophages** M2a 7 Days: M-CS 7 Days: M-CSF 7 Days: M-CSF NRP2 Expression on 24 hours: +100ng/ml LPS -24 hours: +20ng/ml IL-4 + 10² 10³ 10⁴ 10⁵ 10⁶ **Human Primary Macrophages** 20ng/ml IFNy 20ng/ml IL-13 Comp-FL3-A :: NRP2 APC-A Como-FL3-A :: NRR2 APC-A Comp-FL3-A :: NRP2 APC-A Ctrl=Control (mlgG1) Ctrl NRP2 Signal MFI = Median Fluorescent Intensity SEM = standard error of the mean **Figure 11.** Histogram representation of NRP2 expression detected on the cell surface of primary human inducible Tregs on Day 0, 4 and 6 generated from CD4+ naïve T cells. Bar graph representation of NRP2 MFI mean values +/- SEM. 10¹ 10³ 10 10¹ 10³ 10⁵ 10¹ 10³ 10⁹ M0 M1 M2a Ctrl Comp-FL3-A :: NRP2 APC-A Comp-FL3-A :: NRP2 APC-A Comp-FL3-A :: NRP2 APC-A Figure 12. *in vivo* NRP2 Expression Ctrl NRP2 Signal Ctrl= Control (2nd Antibody Alone) MFI = Median Fluorescent Intensit SEM = standard error of the mean **NRP2** Expression **A)** Figure 8. Histogram representation of NRP2 expression detected on the cell surface of various in **NRP2** Expression B lm m u n e C e l l s Immune Cells vitro generated primary macrophages cells (M0, M1, M2a) generated from CD14+CD16-BALF LUNG monocytes. Bar graph representation of NRP2 mean fluorescent intensity (MFI) mean values +/-Naive SEM. Naive +LPS +LPS 400000 ● Ctrl ● Ctrl Figure 9. NRP2 Expression on Human THP-1 Cell Line 30000 M₂a 20000 24 hours: 100ng/ml PMA 24 hours: 100ng/ml PMA **24 hours:** 100ng/ml PMA NRP2 Expression on THP-1 **24 hours:** 100ng/ml PMA **24 hours:** 100ng/ml PMA +100ng/ml **24 hours:** 100ng/ml PMA 100000 **Differentiated Macrophages** LPS + 20ng/ml IFNy +20ng/ml IL-4 + 20ng/ml IL-13 20000 15000 -10² 10⁴ 10⁰ 10² 10⁴ MO M1 M2a Comp-FL3-A :: NRP2 APC-A Comp-FL3-A :: NRP2 APC-A Comp-FL3-A :: NRP2 APC-A NRP2 expression on immune cells upon Ctrl \mathbf{C} 4 hours systemic LPS treatment NRP2 Expressio NRP2 Expression Ctrl= Control (2nd Antibody Alone MFI = Median Fluorescent Intensit Following Cell Surface Following Endosoma SEM = standard error of the mean Ctrl **TLR Stimulation TLR Stimulation** 25000 NRP2 Signal NRP2 Signal Ctrl Naive 20000 LPS Treated 15000 NRP2 Expression Following NRP2 Expression Following Cell Surface TLR Stimulation Endosomal TLR Stimulation Poly(I:C) LMW OC oches oches have cells cells cells CpG B Pam3CSK4 CHI LPS ESL' HALM SCARA T.FLA Ctrl= Control (2nd Antibody Alone MFI = Median Fluorescent Intensity FL3-A :: aaM-647 APC-A SEM = standard error of the mean FL3-A :: aaM-647 APC-A Figure 12. Scattered plot of NRP2 cell surface expression detected on the cell surface of Figure 9. A) Histogram representation of NRP2 expression detected on the cell surface of immune cells in A) BALF (alveolar macrophages, neutrophils & inflammatory monocytes), B) various in vitro generated myeloid cells (M0, M1, M2a) from THP-1 Cell line and Bar graph lung tissue, (alveolar macrophages, neutrophils, inflammatory monocytes, patrolling monocytes representation of NRP2 MFI mean values +/- SEM. B) Histogram representation of NRP2 and dendritic cells) **C)** spleen (B cells, neutrophils, dendritic cells, CD4+ T cells, CD11b+ myeloid expression detected on the cell surface of M0 THP-1 derived cells stimulated with various TLR cells, inflammatory monocytes and patrolling monocytes) of animals challenged with LPS. Mean ligands as indicated and bar graph of NRP2 MFI mean values +/- SEM. values +/- SEM.

Conclusions

• NRP2 was identified as specific binding partner for ATYR1923 (Paz et al. Keystone Poster 2019; Xu et al. ATS Poster #P1173) • NRP2 was expressed within the granulomas of both lung and skin biopsies obtained from sarcoidosis patients, predominantly localized within the inner structure of the granuloma where Langham's giant cells (myeloid origin) reside

• NRP2 was highly expressed on macrophages, dendritic cells and Tregs, which are all cell types involved in granuloma formation • NRP2 was highly expressed following immunostimulation (TLR agonists) in both *in vitro* and *in vivo* systems We clearly show that NRP2 expression can be detected on key immune cells known to play an important role in inflammation and granuloma formation. These findings highlight the potential of ATYR1923 to exert its effect on various immune cells directly related to the pathology of the target patient population.

References

Paz S, Polizzi C, Chu D, Burkart C, King D, Ogilvie K, Rosengren S. ATYR1923 Reduces Neutrophil Infiltration in an Acute Lipopolysaccharide (LPS) Lung injury Model. 2019 Keystone Symposia Conference. B7: Myeloid Cells, Santa Fe, NM. Poster Link Xu Z, Chong Y, Crampton S, Adams R, Rauch K, Paz S, Chu D, Zhai L, Burman L, Ampudia J, Rosengren S, King D, Nangle L. ATYR1923 Specifically Binds to Neureopilin-2, a Novel Therapeutic Target for the Treatment of Immune-Mediated Diseases. ATS 2020. Abstract Link Broos, EB, van Nimwegen M, Hoogsteden HC, Hendriks RW, Kool M, ven der Blink B. Granuloma formation in pulmonary sarcoidosis. Frontiers in Immunology 4, 437 (2013). https://www.frontiersin.org/article/10.3389/fimmu.2013.00437 Inaoka, P.T., Shono, M., Kamada, M. et al. Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis. J Biomed Sci 26, 45 (2019). https://doi.org/10.1186/s12929-019-0537-6 Miedema, J.R., Kaiser, Y.K., Broos, C.E., Wijsenbeek, M.S., Grunewald, J., Kool, M. Th17-lineage cells in pulmonary sarcoidosis and Lofgren's syndrome: Friend or foe?. J of Autoimmunity 87, 82-89 (2018). https://doi.org/10.1016/j.jaut.2017.12.012



